[{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaginal Ring to Reduce the Risk of HIV Infection for Women in non-EU Countries with High Disease Burden","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Dapivirine
The dapivirine ring received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use through EU-M4all procedure, Prequalification from the World Health Organization (WHO), a WHO recommendation for use and approval in Zimbabwe.
EMA’s human medicines committee has adopted a positive opinion for Dapivirine Vaginal Ring used to reduce the risk of infection with the human immunodeficiency virus type 1 (HIV-1), in combination with safer sex practices when oral pre-exposure prophylaxis (PrEP) is not used.